At the time of writing, Gilead Sciences, Inc [GILD] stock is trading at $95.59, up 1.85%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The GILD shares have gain 2.74% over the last week, with a monthly amount glided 1.25%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on January 10, 2025, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $113 from $87. On November 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $110 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $125 on November 14, 2024. Maxim Group downgraded its rating to a Hold. Leerink Partners upgraded its rating to Outperform for this stock on October 21, 2024, and upped its price target to $96. In a note dated October 17, 2024, Bernstein initiated an Outperform rating and provided a target price of $105 on this stock.
For the past year, the stock price of Gilead Sciences, Inc fluctuated between $62.07 and $98.90. Currently, Wall Street analysts expect the stock to reach $88.88 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $95.59 at the most recent close of the market. An investor can expect a potential drop of -7.02% based on the average GILD price forecast.
Analyzing the GILD fundamentals
According to Gilead Sciences, Inc [NASDAQ:GILD], the company’s sales were 28.27B for trailing twelve months, which represents an 7.05% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.3%, Pretax Profit Margin comes in at 0.01%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.01 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 94.47 points at the first support level, and at 93.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 96.32, and for the 2nd resistance point, it is at 97.05.
Ratios To Look Out For
It is important to note that Gilead Sciences, Inc [NASDAQ:GILD] has a current ratio of 1.26. Further, the Quick Ratio stands at 1.10, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 4.21, the price to book ratio is 6.45 and price to earnings (TTM) ratio is 1077.68.
Transactions by insiders
Recent insider trading involved Dickinson Andrew D, Chief Financial Officer, that happened on Jan 15 ’25 when 2500.0 shares were sold. Officer, ANDREW DICKINSON completed a deal on Jan 15 ’25 to buy 2500.0 shares. Meanwhile, 10% Owner GILEAD SCIENCES, INC. bought 0.94 million shares on Dec 19 ’24.
